American Heart Association (AHA) Scientific Sessions 2024

Chicago, Illinois, US 16 November 2024 - 18 November 2024

BP target in diabetics: How low should we go?

15 Jan 2025 by

Intensive blood-pressure (BP) lowering treatment targeted at a tighter systolic BP (SBP) yields cardiovascular benefits in Chinese patients with type 2 diabetes (T2D) and elevated BP in the randomized BPROAD* trial.

BP target in diabetics: How low should we go?

15 Jan 2025

Potassium binder allows optimized MRA therapy in hyperkalaemic HFrEF patients

15 Jan 2025 by

Treatment with the potassium binder sodium zirconium cyclosilicate (SZC) stabilizes potassium levels in patients with heart failure with reduced ejection fraction (HFrEF) during spironolactone optimization, as shown in the prospective, randomized-withdrawal REALIZE-K trial.

Potassium binder allows optimized MRA therapy in hyperkalaemic HFrEF patients

15 Jan 2025

Mavacamten obviates long-term need for invasive septal reduction therapy in obstructive HCM

07 Jan 2025 by

Treatment with the allosteric cardiac myosin inhibitor mavacamten in severely symptomatic patients with obstructive HCM allows for the deferral of invasive SRT for nearly 2.5 years, as shown in the end-of-trial results of VALOR-HCM presented at AHA 2024

Mavacamten obviates long-term need for invasive septal reduction therapy in obstructive HCM

07 Jan 2025

Lonely people prone to incident AF due to unhealthy behaviours

22 Dec 2024 by

Individuals who are lonely appear to be at an increased risk of incident atrial fibrillation (AF), driven by unhealthy behaviours, suggests a study presented at AHA 2024 Scientific Sessions. In addition, women tend to suffer more from the harmful effects of loneliness.

Lonely people prone to incident AF due to unhealthy behaviours

22 Dec 2024

Cannabis users at greater risk of heart attack, stroke

21 Dec 2024 by

The use of cannabis appears to contribute to a higher risk of myocardial infarction (MI) and stroke, with a similar but rising trend in ischaemic and haemorrhagic stroke, as shown by the results of a study presented at the AHA Scientific Sessions 2024.

Cannabis users at greater risk of heart attack, stroke

21 Dec 2024

Obicetrapib cuts LDL-C in patients with HeFH

21 Dec 2024 by

Treatment with obicetrapib, a CETP* inhibitor, significantly reduced low-density lipoprotein cholesterol (LDL-C) levels for up to 1 year in patients with heterozygous familial hypercholesterolaemia (HeFH), despite being on maximally tolerated lipid-lowering therapy, according to the BROOKLYN trial presented at AHA 2024.

Obicetrapib cuts LDL-C in patients with HeFH

21 Dec 2024

Tirzepatide reduces CV death, worsening HF in obese patients with HFpEF

18 Dec 2024 by

Treatment with tirzepatide reduced the risk of cardiovascular (CV) death and worsening heart failure (HF) in patients with HF with preserved ejection fraction (HFpEF) and obesity, according to the SUMMIT trial presented at AHA 2024.

Tirzepatide reduces CV death, worsening HF in obese patients with HFpEF

18 Dec 2024

Sacubitril/valsartan protects against chemo-induced heart damage

12 Dec 2024 by

Use of the common heart failure medication sacubitril/valsartan helps reduce cardiotoxicity in high-risk cancer patients undergoing anthracycline therapy, according to the results of the SARAH trial.

Sacubitril/valsartan protects against chemo-induced heart damage

12 Dec 2024

Nasal spray form of common diuretic holds promise for managing oedema in HF

11 Dec 2024 by

Findings from the RSQ-777-02 trial demonstrate the ability of a novel intranasal formulation of bumetanide, a standard loop diuretic, to reduce tissue swelling caused by heart failure (HF) as effectively as conventional oral and IV formulations.

Nasal spray form of common diuretic holds promise for managing oedema in HF

11 Dec 2024

Pushing BP levels to lower targets better for cardioprotection in T2D

10 Dec 2024 by

Intensive systolic blood pressure (BP)-lowering treatment to reach target levels of less than 120 mm Hg is more beneficial than standard treatment in terms of reducing the risk of major cardiovascular events in Chinese patients with type 2 diabetes (T2D) and elevated BP, according to data from the BPROAD* trial.

Pushing BP levels to lower targets better for cardioprotection in T2D

10 Dec 2024